Brief: Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx’S Ongoing Phase III Tiger-Pac Clinical Trial
29/04/2025 13:39
April 29 (Reuters) - RenovoRx Inc RNXT.O: JOHNS HOPKINS MEDICINE INITIATES PATIENT ENROLLMENT FOR RENOVORX’S ONGOING PHASE III TIGER-PAC CLINICAL TRIAL RENOVORX INC - EXPECTS FULL ENROLLMENT FOR TIGER-PAC TRIAL IN 2025 Source text: ID:nBwbHZsKla Further company coverage: RNXT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer